How to read peptide evidence: grades, citations and thin claims

The peptide space is full of confident claims and thin evidence. Learning to read the strength of a claim protects you more than any single fact. Aminove grades every library entry so you can see, at a glance, how much to trust it.

The grades, strongest first

• Human RCT: randomised controlled trials in people — the strongest routine evidence.
• Human observational: cohorts, case series or regional clinical use — suggestive but bias-prone.
• Animal / preclinical: rodent or lab studies only, which often do not translate to humans.
• Anecdote / community: forums, self-reports and vendor claims — not evidence of efficacy or safety.

Why this matters

The GLP-1 medicines (semaglutide, tirzepatide) sit on large human trials. Most other peptides — BPC-157, TB-500, the growth-hormone secretagogues — rest on animal data and anecdote. A high grade means the evidence is strong; it does not mean a peptide is safe or legal for you.

Legal status varies by country and changes over time; verify locally and consult a licensed clinician.